Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Transgene S.A.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal.
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.
- Gene Therapy, Cell Therapy